On Wednesday, Bharat biotech issued an official statement that the company will conduct a 4th phase of trial to check the efficacy of the vaccine after the ongoing war going on between covishield and covaxin.
The company has also said that it will publish the phase III trials data by July and after that apply for full license. The ongoing twitter war between the two vaccines of India hair started after the reports which says that covishield is more effective as it produces more antibodies then covaxin does.
But Bharat biotech has defended itself by saying that a peer review is yet to be conducted before coming into the conclusions.” A recent comparative report on an evaluation of immunogenicity responses to spike protein after the first and second dose of Indian manufactured vaccines study had lots of flaws.
The journal that stated the comparative report said more antibodies produced by Covishield than COVAXIN. This is not a peer-reviewed publication, nor do it a statistically and scientifically designed study. The study design and conduct reflect an ad hoc analysis, rather than a predetermined hypothesis," the company official statement read.
NCB regional director Sameer Wankhede is not targeting Bollywood, his wife Kranti Redkar told India Today on Monday. He also responded to the allegati...
27th of October is observed as the Black Day. During this day India had invaded the disputed Jammu and Kashmir back in 1947.Alastair Lamb, in his book...